EAM
CNTX icon

Empery Asset Management’s Context Therapeutics CNTX Stock Holding History

Empery Asset Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-358,617
Closed -$954K – 79
2021
Q4 		$954K Buy
+358,617
New +$1.79M 1.99% 14

Other funds holding CNTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Empery Asset Management's CNTX Position: Q1 2022 in Review

Empery Asset Management sold out of Context Therapeutics (CNTX) in Q1 2022, closing a stake of 358,617 shares — an estimated $954K sold.

Empery Asset Management first reported a position in CNTX in Q4 2021 and held it in 1 quarter. The position peaked at $954K in Q4 2021. 16 funds tracked by Wall St. Rank hold CNTX as of Q1 2022.

  • Empery Asset Management reported no remaining Context Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Empery Asset Management sold 358,617 Context Therapeutics shares in Q1 2022, an estimated $954K.
  • Empery Asset Management first reported a position in Context Therapeutics in Q4 2021 and held it in 1 quarter.
  • Empery Asset Management's Context Therapeutics position peaked at $954K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2022.

Based on Empery Asset Management's 13F filing for Q1 2022, filed 16 May 2022.